SML2106
Roflupram
≥98% (HPLC)
Sinónimos:
1-[4-(Difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]phenyl]-3-methyl-1-butanone, FFPM, ZL-n-91
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Productos recomendados
assay
≥98% (HPLC)
form
oil
color
colorless to light brown
storage temp.
2-8°C
SMILES string
O=C(CC(C)C)C1=CC=C(OC(F)F)C(OC2CCOC2)=C1
Biochem/physiol Actions
Roflupram (FFPM) is a potent anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor that was found to suppress inflammasome activation in microglial cells by enhancing autophagy. In microglial BV-2 cells roflupram enhanced the level of microtubule-associated protein 1 light chain 3 II (LC3-II) and decreased the autophagy receptor ubiquitin-binding protein p62 (SQSTM1), enhancing autophagy, reducing the activation of inflammasome and suppressing the production of IL-1β. Roflupram (FFPM) was found to reverse learning and memory deficits in APP/PS1 transgenic mice.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
ACS chemical neuroscience, 8(11), 2381-2392 (2017-06-13)
Inhibition of phosphodiesterase 4 (PDE4) suppressed the inflammatory responses in the brain. However, the underlying mechanisms are poorly understood. Roflupram (ROF) is a novel PDE4 inhibitor. In the present study, we found that ROF enhanced the level of microtubule-associated protein
Journal of medicinal chemistry, 51(24), 7673-7688 (2008-12-04)
Phosphodiesterase 4 catalyzes the hydrolysis of cyclic AMP and is a target for the development of anti-inflammatory agents. We have designed and synthesized a series of phenyl alkyl ketones as PDE4 inhibitors. Among them, 13 compounds were identified as having
Neuropharmacology, 116, 260-269 (2017-01-10)
Thus far, phosphodiesterase-4 (PDE4) inhibitors have not been approved for application in Alzheimer's disease (AD) in a clinical setting due to severe side effects, such as nausea and vomiting. In this study, we investigated the effect of FFPM, a novel
International immunopharmacology, 10(4), 406-411 (2010-01-16)
In the present study, we investigated the effect of classic PDE4 inhibitor rolipram and novel PDE4 inhibitor ZL-n-91 on LPS-induced acute lung injury (ALI) in mice and its mechanism. ALI was induced in ICR mice by instilling intratracheally with LPS
International immunopharmacology, 90, 107176-107176 (2020-11-28)
Roflupram (ROF) is a novel phosphodiesterase 4 inhibitor. We previously found that ROF suppressed the production of pro-inflammatory factors in microglial cells; however, the underlying mechanisms are largely unknown. The present study aimed to elucidate the underlying molecular mechanisms of
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico